Stoke Therapeutics Inc (STOK)
13.90
-0.13
(-0.93%)
USD |
NASDAQ |
May 17, 16:00
13.90
0.00 (0.00%)
After-Hours: 20:00
Stoke Therapeutics Cash from Investing (Quarterly): 9.988M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.988M |
| December 31, 2023 | 14.77M |
| September 30, 2023 | 14.62M |
| June 30, 2023 | 23.47M |
| March 31, 2023 | 53.08M |
| December 31, 2022 | 22.49M |
| September 30, 2022 | 67.26M |
| June 30, 2022 | 0.146M |
| March 31, 2022 | -135.78M |
| December 31, 2021 | 11.80M |
| September 30, 2021 | -5.264M |
| June 30, 2021 | -82.76M |
| March 31, 2021 | -0.204M |
| Date | Value |
|---|---|
| December 31, 2020 | -0.09M |
| September 30, 2020 | -0.269M |
| June 30, 2020 | -0.081M |
| March 31, 2020 | -0.61M |
| December 31, 2019 | -0.569M |
| September 30, 2019 | -0.583M |
| June 30, 2019 | -0.392M |
| March 31, 2019 | -0.09M |
| December 31, 2018 | -0.083M |
| September 30, 2018 | -0.516M |
| June 30, 2018 | -0.30M |
| March 31, 2018 | -0.026M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-135.78M
Minimum
Mar 2022
67.26M
Maximum
Sep 2022
-0.4484M
Average
-0.0855M
Median
Cash from Investing (Quarterly) Benchmarks
| NeuBase Therapeutics Inc | 0.00 |
| iBio Inc | 0.00 |
| Actinium Pharmaceuticals Inc | -0.011M |
| Lixte Biotechnology Holdings Inc | -- |
| Fate Therapeutics Inc | 17.31M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -24.57M |
| Cash from Financing (Quarterly) | 1.717M |
| Free Cash Flow | -85.74M |
| Free Cash Flow Per Share (Quarterly) | -0.5315 |
| Free Cash Flow to Equity (Quarterly) | -24.58M |
| Free Cash Flow Yield | -13.73% |